Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Obshchaya Reanimatologiya ; 18(4):11-19, 2022.
Article in Russian | EMBASE | ID: covidwho-2010542

ABSTRACT

One of the main problems facing intensivists when treating patients with COVID-19 is severe and critical acute respiratory distress syndrome (ARDS) with the underlying viral pneumonia. The current guidelines of the Russian Ministry of Health (Version 15 of 22.02.22) do not include drugs with a lung protective effect. This issue could be solved by administration of a synthetic analogue of leu-enkephalin. Aim. Study the efficacy of a synthetic analogue of leu-enkephalin in ARDS in patients with COVID-19. Materials and methods. The study included 35 patients divided into 2 groups. Group 1 (main) patients (n=15) in addition to standard therapy received a continuous infusion of synthetic analogue of leu-enkephalin at a rate of 5 µg/kg/hour for 5 days. Patients from group 2 (control, n=20) were treated according to the Temporary Guidelines of the Ministry of Health (V.15), but without the synthetic analogue of leu-enkephalin. The radiological data, frequency, severity and evolution of respiratory complications, changes in P/F (PaO2/FiO2) ratio, as well as changes in the scores of prognostic APACHE II, SOFA, and NEWS scales were evaluated. Results. In patients taking the studied drug, the percentage of lung damage did not change with the median (IQR) of 0 [–8;0], while in the control group it increased by approximately 10% with the median (IQR) of +10,0 [+2;+20] (P=0.001). The proportion of patients in group 1 with positive disease evolution within 5–9 days after treatment initiation was significantly higher and reached 46.7 [24.8;69.9]%, whereas in group 2 it was 15.0 [5.2;36.0]% (P=0.04). Also, in group 1, starting from day 4, the median P/F ratio was significantly higher than in group 2 reaching 220 [185;245] versus 127 [111;158], respectively (P=0.014). The need for non-invasive lung ventilation in group 1 on day 7 averaged 6.7%, while in group 2 it was as high as 45.0%, which was significantly higher than in the main group (P=0.013). Conclusions. The use of synthetic analogue of leu-enkephalin according to the specified regimen had a significant impact on the main parameters of the viral pneumonia severity. The results serve as a rationale for the development of a novel effective treatment strategy to supplement the current standard COVID-19 management.

2.
Journal of Pharmaceutical Research International ; 33(41B):79-93, 2021.
Article in English | Web of Science | ID: covidwho-1410099

ABSTRACT

This article presents a proposed insight into the anti-viral potential of silver nanoparticles against novel coronavirus disease (COVID-19). Possible mechanisms of influence of silver nanoparticles on the coronavirus are considered. Models of nanosilver complexes with spike protein of coronavirus amino acids were constructed using computer quantum-chemical modeling. The values of electron density distribution, highest occupied molecular orbital, lowest unoccupied molecular orbital and electron density distribution gradient for each constructed model are obtained. Analysis of the obtained data showed that the most energy-efficient interaction is the formation of the "tryptophan-nanosilver" complex (E=-5856.83 kkal/mol). According to the results of quantum chemical calculations, the most stable complex is the "cysteine-Ag nanoparticles" complex (Delta E = 0.16 a.u.).

3.
Turkish Journal of Physiotherapy and Rehabilitation ; 32(3):8297-8299, 2021.
Article in English | EMBASE | ID: covidwho-1312158

ABSTRACT

The SARS-CoV-2 turned out to be aggressive, and the number of diseases around the world continues to grow to the present. According to observational studies, people with chronic diseases are more a trisk for severe COVID-19 disease. Endocrinologists are faced with new tasks-to inform persons with endocrinopathies as quickly as possible about the risks that their health could potentially cause, a pandemic;on infection prevention methods and management tactics for people with endocrinopathies in the face of a virus-caused disease.

SELECTION OF CITATIONS
SEARCH DETAIL